We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+11.56%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$152M
Cap. Flow
+$78.1M
Cap. Flow %
7.15%
Top 10 Hldgs %
44.59%
Holding
100
New
19
Increased
24
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$27.9M
2
DGX icon
Quest Diagnostics
DGX
+$26.1M
3
CAH icon
Cardinal Health
CAH
+$20.8M
4
LLY icon
Eli Lilly
LLY
+$19.4M
5
CRL icon
Charles River Laboratories
CRL
+$15.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.6M
3
BPMC
Blueprint Medicines
BPMC
+$12.8M
4
KRYS icon
Krystal Biotech
KRYS
+$10.8M
5
BSX icon
Boston Scientific
BSX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
Edwards Lifesciences
EW
$53B
$15.6M 1.43%
200,000
+75,000
+60% +$5.59M
GEHC icon
27
GE HealthCare
GEHC
$32.9B
$14.8M 1.36%
200,000
+50,000
+33% +$3.48M
AZN icon
28
AstraZeneca
AZN
$251B
$14M 1.28%
+100,000
New +$14M
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.84B
$13.1M 1.2%
1,000,000
+325,000
+48% +$4.69M
ORIC icon
30
Oric Pharmaceuticals
ORIC
$1.41B
$12.7M 1.16%
+1,250,000
New +$8.39M
RVMD icon
31
Revolution Medicines
RVMD
$44.4B
$12M 1.09%
325,000
+75,000
+30% +$2.88M
ETNB
32
DELISTED
89bio
ETNB
$10.3M 0.94%
1,050,000
– –
PEN icon
33
Penumbra
PEN
$12.8B
$10.3M 0.94%
40,000
+5,000
+14% +$1.36M
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.47B
$9.44M 0.86%
200,000
– –
INSP icon
35
Inspire Medical Systems
INSP
$1.73B
$9.08M 0.83%
70,000
+5,000
+8% +$725K
ACHC icon
36
Acadia Healthcare
ACHC
$2.96B
$9.08M 0.83%
400,000
+150,000
+60% +$3.55M
BEAM icon
37
Beam Therapeutics
BEAM
$2.82B
$8.51M 0.78%
+500,000
New +$8.71M
HOLX
38
DELISTED
Hologic
HOLX
$8.14M 0.75%
+125,000
New +$7.49M
TARS icon
39
Tarsus Pharmaceuticals
TARS
$2.97B
$8.1M 0.74%
200,000
– –
RZLT icon
40
Rezolute
RZLT
$451M
$8.03M 0.74%
1,800,000
+1,300,000
+260% +$4.83M
RYTM icon
41
Rhythm Pharmaceuticals
RYTM
$7.95B
$7.58M 0.69%
+120,000
New +$7.35M
BAX icon
42
Baxter International
BAX
$14.4B
$7.57M 0.69%
250,000
-250,000
-50% -$7.58M
ABBV icon
43
AbbVie
ABBV
$438B
$7.42M 0.68%
40,000
-20,000
-33% -$3.72M
MCK icon
44
McKesson
MCK
$103B
$7.33M 0.67%
10,000
-2,000
-17% -$1.41M
ROIV icon
45
Roivant Sciences
ROIV
$25.8B
$6.76M 0.62%
600,000
– –
IRTC icon
46
iRhythm Holdings
IRTC
$4.11B
$6.16M 0.56%
+40,000
New +$5.17M
A icon
47
Agilent Technologies
A
$42B
$5.9M 0.54%
+50,000
New +$5.54M
RGNX icon
48
Regenxbio
RGNX
$688M
$5.75M 0.53%
700,000
-225,000
-24% -$1.88M
VRNA
49
DELISTED
Verona Pharma
VRNA
$5.67M 0.52%
60,000
-55,000
-48% -$4.07M
ALHC icon
50
Alignment Healthcare
ALHC
$2.86B
$5.6M 0.51%
400,000
+200,000
+100% +$3.22M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Integral Health Asset Management held 100 positions worth $1.09B, up 16% from $940M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $78.1M of net new capital in Q2 2025, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Boston Scientific, an estimated $10.1M trimmed.

  • Integral Health Asset Management's largest Q2 2025 buy was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.
  • Integral Health Asset Management added most to BrightSpring Health Services in Q2 2025, an estimated $9.91M increase.
  • Integral Health Asset Management's biggest Q2 2025 reduction was Boston Scientific, cutting an estimated $10.1M.
  • Integral Health Asset Management fully exited Gilead Sciences in Q2 2025, selling an estimated $19.6M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.09B portfolio in Q2 2025.
  • Integral Health Asset Management opened 19 new positions and closed 28 in Q2 2025.
  • Integral Health Asset Management's portfolio value rose 16% quarter-over-quarter to $1.09B.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.